Abbott acquires Aventis’ Mavik
Executive Summary
Abbott Labs acquires full manufacturing and commercial rights to Aventis' cardiovascular drugs Mavik and Tarka for $300 mil. plus royalties. Abbott already holds marketing rights to Mavik (trandolapril) and Tarka (trandolapril/verapamil) in the U.S. and other countries under a 1991 licensing deal. Aventis will retain rights to the products in Japan. Combined global sales topped $200 mil. in 2003; Abbott believes sales of the two drugs could eventually reach $700 mil. The divestiture is not related to the Sanofi merger, Aventis says...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.